In Brief: Cardiac Pathways
This article was originally published in The Gray Sheet
Cardiac Pathways: Receives investigational device exemption from FDA for its Arrythmia Mapping System cardiac ablation product for the treatment of tachyarrhythmias in the right atrium. Trials of the system, which utilizes Cardiac Pathways' 64-electrode Mercator "basket" mapping catheter, will take place at five U.S. sites and compare the AMS to other "commercially available mapping catheters." The Sunnyvale, California firm received IDE approval in February for use of the system in the left ventricle ("The Gray Sheet" Feb. 12, In Brief)...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.